Multiple Sclerosis Clinical Trial
— TaiChi-SMOfficial title:
The Combined Impact of a Structured Tai Chi Exercise Program on Selected Clinical Aspects and Quality of Life of Patients With Multiple Sclerosis
Verified date | July 2022 |
Source | Comenius University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system (CNS). The clinical picture is very variable, ultimately resulting in disability. Disease attacks manifest themselves depending on the location of the CNS damaged by inflammation, demyelination, axonal loss and gliosis. The most common manifestations include motor disorders with the development of stiffness, balance and coordination, cognition, fatigue and depression. In the long term, most patients with MS will achieve significant and irreversible incapacitation. Immunomodulatory therapy is designed to reduce disease activity, slowing progression, but only to a certain extent. A significant benefit, but little researched, is physical exercise. Tai Chi has a positive effect on various neurological diseases. In recent studies, Tai Chi has shown improvements in coordination and balance, depression, anxiety, cognition and overall quality of life in patients with MS. The aim of the project is to assess the therapeutic value of structured Tai Chi exercise based on published clinical work.
Status | Completed |
Enrollment | 25 |
Est. completion date | January 31, 2022 |
Est. primary completion date | January 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 60 Years |
Eligibility | Inclusion Criteria: 1. clinically defined MS, 2. age from 20 to 60 years, 3. and the ability to stand and walk independently at least 200 meters without an assistive device. Exclusion Criteria: 1. clinical MS exacerbation during the study, 2. disease-modifying drug change during the study, 3. pregnancy, 4. involvement in any other exercise programme, 5. severe cognitive deficit (defined by Montreal Cognitive Assessment score =19), and 6. any other health condition that would interfere with an exercise programme (such as musculoskeletal disorder, lung, or heart disease). |
Country | Name | City | State |
---|---|---|---|
Slovakia | 2nd Department of Neurology, Faculty of Medicine COMENIUS UNIVERSITY BRATISLAVA | Bratislava | Slovak Republic |
Lead Sponsor | Collaborator |
---|---|
Comenius University |
Slovakia,
Alvarenga-Filho H, Sacramento PM, Ferreira TB, Hygino J, Abreu JEC, Carvalho SR, Wing AC, Alvarenga RMP, Bento CAM. Combined exercise training reduces fatigue and modulates the cytokine profile of T-cells from multiple sclerosis patients in response to ne — View Citation
Arnett PA, Strober LB. Cognitive and neurobehavioral features in multiple sclerosis. Expert Rev Neurother. 2011 Mar;11(3):411-24. doi: 10.1586/ern.11.12. Review. — View Citation
Azimzadeh E, Hosseini MA, Nourozi K, Davidson PM. Effect of Tai Chi Chuan on balance in women with multiple sclerosis. Complement Ther Clin Pract. 2015 Feb;21(1):57-60. doi: 10.1016/j.ctcp.2014.09.002. Epub 2014 Nov 27. — View Citation
Burschka JM, Keune PM, Oy UH, Oschmann P, Kuhn P. Mindfulness-based interventions in multiple sclerosis: beneficial effects of Tai Chi on balance, coordination, fatigue and depression. BMC Neurol. 2014 Aug 23;14:165. doi: 10.1186/s12883-014-0165-4. — View Citation
Gibson JC, Summers GD. Bone health in multiple sclerosis. Osteoporos Int. 2011 Dec;22(12):2935-49. doi: 10.1007/s00198-011-1644-8. Epub 2011 May 21. Review. — View Citation
Husted C, Pham L, Hekking A, Niederman R. Improving quality of life for people with chronic conditions: the example of t'ai chi and multiple sclerosis. Altern Ther Health Med. 1999 Sep;5(5):70-4. — View Citation
Latimer-Cheung AE, Pilutti LA, Hicks AL, Martin Ginis KA, Fenuta AM, MacKibbon KA, Motl RW. Effects of exercise training on fitness, mobility, fatigue, and health-related quality of life among adults with multiple sclerosis: a systematic review to inform — View Citation
Wens I, Keytsman C, Deckx N, Cools N, Dalgas U, Eijnde BO. Brain derived neurotrophic factor in multiple sclerosis: effect of 24 weeks endurance and resistance training. Eur J Neurol. 2016 Jun;23(6):1028-35. doi: 10.1111/ene.12976. Epub 2016 Mar 16. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | V0 visit- Static posturography | Static posturography- eyes closed on the foam rubber in mm2, Objective test (instrumental), Score interpretation: The more, the worse. | 1. day | |
Primary | V1 visit- Static posturography | Static posturography- eyes closed on the foam rubber in mm2, Objective test (instrumental), Score interpretation: The more, the worse. | 3 months after V0 visit | |
Primary | V2 visit- Static posturography | Static posturography- eyes closed on the foam rubber in mm2, Objective test (instrumental), Score interpretation: The more, the worse. | 6 months after V0 visit | |
Primary | V3 visit- Static posturography | Static posturography- eyes closed on the foam rubber in mm2, Objective test (instrumental), Score interpretation: The more, the worse. | 9 months after V0 visit | |
Primary | V4 visit- Static posturography | Static posturography- eyes closed on the foam rubber in mm2, Objective test (instrumental), Score interpretation: The more, the worse. | 12 months after V0 visit | |
Primary | V0 visit- Static posturography LI | Static posturography- - LI - line integral in mm, Objective test (instrumental), Score interpretation: The more, the worse. | 1. day | |
Primary | V1 visit- Static posturography LI | Static posturography- - LI - line integral in mm, Objective test (instrumental), Score interpretation: The more, the worse. | 3 months after V0 visit | |
Primary | V2 visit- Static posturography LI | Static posturography- - LI - line integral in mm, Objective test (instrumental), Score interpretation: The more, the worse. | 6 months after V0 visit | |
Primary | V3 visit- Static posturography LI | Static posturography- - LI - line integral in mm, Objective test (instrumental), Score interpretation: The more, the worse. | 9 months after V0 visit | |
Primary | V4 visit- Static posturography LI | Static posturography- - LI - line integral in mm, Objective test (instrumental), Score interpretation: The more, the worse. | 12 months after V0 visit | |
Primary | V0 visit- Static posturography TA | Static posturography- TA - total area in mm2, Objective test (instrumental), Score interpretation: The more, the worse. | 1. day | |
Primary | V1 visit- Static posturography TA | Static posturography- TA - total area in mm2, Objective test (instrumental), Score interpretation: The more, the worse. | 3 months after V0 visit | |
Primary | V2 visit- Static posturography TA | Static posturography- TA - total area in mm2, Objective test (instrumental), Score interpretation: The more, the worse. | 6 months after V0 visit | |
Primary | V3 visit- Static posturography TA | Static posturography- TA - total area in mm2, Objective test (instrumental), Score interpretation: The more, the worse. | 9 months after V0 visit | |
Primary | V4 visit- Static posturography TA | Static posturography- TA - total area in mm2, Objective test (instrumental), Score interpretation: The more, the worse. | 12 months after V0 visit | |
Primary | V0 visit- Static posturography RMS | Static posturography- - RMS - root mean square in mm, Objective test (instrumental), Score interpretation: The more, the worse. | 1. day | |
Primary | V1 visit- Static posturography RMS | Static posturography- - RMS - root mean square in mm, Objective test (instrumental), Score interpretation: The more, the worse. | 3 months after V0 visit | |
Primary | V2 visit- Static posturography RMS | Static posturography- - RMS - root mean square in mm, Objective test (instrumental), Score interpretation: The more, the worse. | 6 months after V0 visit | |
Primary | V3 visit- Static posturography RMS | Static posturography- - RMS - root mean square in mm, Objective test (instrumental), Score interpretation: The more, the worse. | 9 months after V0 visit | |
Primary | V4 visit- Static posturography RMS | Static posturography- - RMS - root mean square in mm, Objective test (instrumental), Score interpretation: The more, the worse. | 12 months after V0 visit | |
Primary | V0 visit- Mini-BESTest | Mini-BESTest - Balance Evaluation Systems Test measure in points from 0 - 28. Objective test (clinical), The less, the worse.
The Mini-BESTest consists of 14 tasks that assess static, proactive, and reactive balance. This balance measure is a shorter version of the original 27-item BESTest and takes only 15 minutes to administer. The mini-BESTest may be more appropriate and effective for ambulatory people with MS with relatively few walking disabilities. Higher scores mean better outcome. |
1. day | |
Primary | V1 visit- Mini-BESTest | Mini-BESTest - Balance Evaluation Systems Test measure in points from 0 - 28. Objective test (clinical), The less, the worse.
The Mini-BESTest consists of 14 tasks that assess static, proactive, and reactive balance. This balance measure is a shorter version of the original 27-item BESTest and takes only 15 minutes to administer. The mini-BESTest may be more appropriate and effective for ambulatory people with MS with relatively few walking disabilities. Higher scores mean better outcome. |
3 months after V0 visit | |
Primary | V2 visit- Mini-BESTest | Mini-BESTest - Balance Evaluation Systems Test measure in points from 0 - 28. Objective test (clinical), The less, the worse.
The Mini-BESTest consists of 14 tasks that assess static, proactive, and reactive balance. This balance measure is a shorter version of the original 27-item BESTest and takes only 15 minutes to administer. The mini-BESTest may be more appropriate and effective for ambulatory people with MS with relatively few walking disabilities. Higher scores mean better outcome. |
6 months after V0 visit | |
Primary | V3 visit- Mini-BESTest | Mini-BESTest - Balance Evaluation Systems Test measure in points from 0 - 28. Objective test (clinical), The less, the worse.
The Mini-BESTest consists of 14 tasks that assess static, proactive, and reactive balance. This balance measure is a shorter version of the original 27-item BESTest and takes only 15 minutes to administer. The mini-BESTest may be more appropriate and effective for ambulatory people with MS with relatively few walking disabilities. Higher scores mean better outcome. |
9 months after V0 visit | |
Primary | V4 visit- Mini-BESTest | Mini-BESTest - Balance Evaluation Systems Test measure in points from 0 - 28. Objective test (clinical), The less, the worse.
The Mini-BESTest consists of 14 tasks that assess static, proactive, and reactive balance. This balance measure is a shorter version of the original 27-item BESTest and takes only 15 minutes to administer. The mini-BESTest may be more appropriate and effective for ambulatory people with MS with relatively few walking disabilities. Higher scores mean better outcome. |
12 months after V0 visit | |
Secondary | V0 visit- EDSS - Expanded disability status scale | EDSS - Expanded disability status scale in points from 0 - 10, Ordinal rating system, The more, the worse | 1. day | |
Secondary | V1 visit- EDSS - Expanded disability status scale | EDSS - Expanded disability status scale in points from 0 - 10, Ordinal rating system, The more, the worse | 3 months after V0 visit | |
Secondary | V2 visit- EDSS - Expanded disability status scale | EDSS - Expanded disability status scale in points from 0 - 10, Ordinal rating system, The more, the worse | 6 months after V0 visit | |
Secondary | V3 visit- EDSS - Expanded disability status scale | EDSS - Expanded disability status scale in points from 0 - 10, Ordinal rating system, The more, the worse | 9 months after V0 visit | |
Secondary | V4 visit- EDSS - Expanded disability status scale | EDSS - Expanded disability status scale in points from 0 - 10, Ordinal rating system, The more, the worse | 12 months after V0 visit | |
Secondary | V0 visit- T25FW - Timed 25-foot walk test | T25FW - Timed 25-foot walk test in seconds, Objective test (clinical), The more, the worse.
The T25-FW is a quantitative mobility and leg function performance test based on a timed 25-walk. The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the patient walk back the same distance. Patients may use assistive devices when doing this task. The score for the T25-FW is the average of the two completed trials. Higher scores mean worse outcome. |
1. day | |
Secondary | V1 visit- T25FW - Timed 25-foot walk test | T25FW - Timed 25-foot walk test in seconds, Objective test (clinical), The more, the worse.
The T25-FW is a quantitative mobility and leg function performance test based on a timed 25-walk. The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the patient walk back the same distance. Patients may use assistive devices when doing this task. The score for the T25-FW is the average of the two completed trials. Higher scores mean worse outcome. |
3 months after V0 visit | |
Secondary | V2 visit- T25FW - Timed 25-foot walk test | T25FW - Timed 25-foot walk test in seconds, Objective test (clinical), The more, the worse.
The T25-FW is a quantitative mobility and leg function performance test based on a timed 25-walk. The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the patient walk back the same distance. Patients may use assistive devices when doing this task. The score for the T25-FW is the average of the two completed trials. Higher scores mean worse outcome. |
6 months after V0 visit | |
Secondary | V3 visit- T25FW - Timed 25-foot walk test | T25FW - Timed 25-foot walk test in seconds, Objective test (clinical), The more, the worse.
The T25-FW is a quantitative mobility and leg function performance test based on a timed 25-walk. The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the patient walk back the same distance. Patients may use assistive devices when doing this task. The score for the T25-FW is the average of the two completed trials. Higher scores mean worse outcome. |
9 months after V0 visit | |
Secondary | V4 visit- T25FW - Timed 25-foot walk test | T25FW - Timed 25-foot walk test in seconds, Objective test (clinical), The more, the worse.
The T25-FW is a quantitative mobility and leg function performance test based on a timed 25-walk. The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the patient walk back the same distance. Patients may use assistive devices when doing this task. The score for the T25-FW is the average of the two completed trials. Higher scores mean worse outcome. |
12 months after V0 visit | |
Secondary | V0 visit- PASAT - Paced Auditory Serial Addition | PASAT - Paced Auditory Serial Addition in correct items from 0 - 60, Scale, The less, the worse.
The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability. The PASAT is presented using audio cassette tape or compact disk to ensure standardization in the rate of stimulus presentation. The score for the PASAT is the total number correct out of 60 possible answers. Higher scores mean better outcome. |
1. day | |
Secondary | V1 visit- PASAT - Paced Auditory Serial Addition | PASAT - Paced Auditory Serial Addition in correct items from 0 - 60, Scale, The less, the worse.
The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability. The PASAT is presented using audio cassette tape or compact disk to ensure standardization in the rate of stimulus presentation. The score for the PASAT is the total number correct out of 60 possible answers. Higher scores mean better outcome. |
3 months after V0 visit | |
Secondary | V2 visit- PASAT - Paced Auditory Serial Addition | PASAT - Paced Auditory Serial Addition in correct items from 0 - 60, Scale, The less, the worse.
The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability. The PASAT is presented using audio cassette tape or compact disk to ensure standardization in the rate of stimulus presentation. The score for the PASAT is the total number correct out of 60 possible answers. Higher scores mean better outcome. |
6 months after V0 visit | |
Secondary | V3 visit- PASAT - Paced Auditory Serial Addition | PASAT - Paced Auditory Serial Addition in correct items from 0 - 60, Scale, The less, the worse.
The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability. The PASAT is presented using audio cassette tape or compact disk to ensure standardization in the rate of stimulus presentation. The score for the PASAT is the total number correct out of 60 possible answers. Higher scores mean better outcome. |
9 months after V0 visit | |
Secondary | V4 visit- PASAT - Paced Auditory Serial Addition | PASAT - Paced Auditory Serial Addition in correct items from 0 - 60, Scale, The less, the worse.
The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability. The PASAT is presented using audio cassette tape or compact disk to ensure standardization in the rate of stimulus presentation. The score for the PASAT is the total number correct out of 60 possible answers. Higher scores mean better outcome. |
12 months after V0 visit | |
Secondary | V0 visit- SDMT - Symbol Digit Modalities Test | SDMT - Symbol Digit Modalities Test in correct items from 0 - 110, Scale, The less, the worse.
The Symbol Digit Modalities Test (SDMT) is the most sensitive screening metric of neurocognitive function in multiple sclerosis (MS) and is consistently interpreted as a measure of information processing speed (IPS), attention and working memory. It is a paper-pencil measure which requires an individual to substitute digits for abstract symbols using a reference key. Higher scores mean better outcome. |
1. day | |
Secondary | V1 visit- SDMT - Symbol Digit Modalities Test | SDMT - Symbol Digit Modalities Test in correct items from 0 - 110, Scale, The less, the worse.
The Symbol Digit Modalities Test (SDMT) is the most sensitive screening metric of neurocognitive function in multiple sclerosis (MS) and is consistently interpreted as a measure of information processing speed (IPS), attention and working memory. It is a paper-pencil measure which requires an individual to substitute digits for abstract symbols using a reference key. Higher scores mean better outcome. |
3 months after V0 visit | |
Secondary | V2 visit- SDMT - Symbol Digit Modalities Test | SDMT - Symbol Digit Modalities Test in correct items from 0 - 110, Scale, The less, the worse.
The Symbol Digit Modalities Test (SDMT) is the most sensitive screening metric of neurocognitive function in multiple sclerosis (MS) and is consistently interpreted as a measure of information processing speed (IPS), attention and working memory. It is a paper-pencil measure which requires an individual to substitute digits for abstract symbols using a reference key. Higher scores mean better outcome. |
6 months after V0 visit | |
Secondary | V3 visit- SDMT - Symbol Digit Modalities Test | SDMT - Symbol Digit Modalities Test in correct items from 0 - 110, Scale, The less, the worse.
The Symbol Digit Modalities Test (SDMT) is the most sensitive screening metric of neurocognitive function in multiple sclerosis (MS) and is consistently interpreted as a measure of information processing speed (IPS), attention and working memory. It is a paper-pencil measure which requires an individual to substitute digits for abstract symbols using a reference key. Higher scores mean better outcome. |
9 months after V0 visit | |
Secondary | V4 visit- SDMT - Symbol Digit Modalities Test | SDMT - Symbol Digit Modalities Test in correct items from 0 - 110, Scale, The less, the worse.
The Symbol Digit Modalities Test (SDMT) is the most sensitive screening metric of neurocognitive function in multiple sclerosis (MS) and is consistently interpreted as a measure of information processing speed (IPS), attention and working memory. It is a paper-pencil measure which requires an individual to substitute digits for abstract symbols using a reference key. Higher scores mean better outcome. |
12 months after V0 visit | |
Secondary | V0 visit- EQ-5D - European Quality of Life Questionnaire | The EQ-5D is a measure of self-reported health outcomes that is applicable to a wide range of health conditions and treatments. It consists of two parts: a descriptive system (Part I) and a visual analogue scale (VAS) (Part II). Part I of the scale consists of 5 single-item dimensions including: mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has a 3 point response scale designed to indicate the level of the problem. Part II uses a vertical graduated VAS (thermometer) to measure health status, ranging from worst imaginable health state to best imaginable health state. Descriptive data from the 5 dimensions of Part I can be used to generate a health-related quality of life profile for the subject. Higher scores mean worse outcome. Part II is scored from 0 to 100. The score from Part II can be used to track changes in health, on an individual or group level, over time. Higher scores mean better outcome. | 1. day | |
Secondary | V1 visit- EQ-5D - European Quality of Life Questionnaire | The EQ-5D is a measure of self-reported health outcomes that is applicable to a wide range of health conditions and treatments. It consists of two parts: a descriptive system (Part I) and a visual analogue scale (VAS) (Part II). Part I of the scale consists of 5 single-item dimensions including: mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has a 3 point response scale designed to indicate the level of the problem. Part II uses a vertical graduated VAS (thermometer) to measure health status, ranging from worst imaginable health state to best imaginable health state. Descriptive data from the 5 dimensions of Part I can be used to generate a health-related quality of life profile for the subject. Higher scores mean worse outcome. Part II is scored from 0 to 100. The score from Part II can be used to track changes in health, on an individual or group level, over time. Higher scores mean better outcome. | 3 months after V0 visit | |
Secondary | V2 visit- EQ-5D - European Quality of Life Questionnaire | The EQ-5D is a measure of self-reported health outcomes that is applicable to a wide range of health conditions and treatments. It consists of two parts: a descriptive system (Part I) and a visual analogue scale (VAS) (Part II). Part I of the scale consists of 5 single-item dimensions including: mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has a 3 point response scale designed to indicate the level of the problem. Part II uses a vertical graduated VAS (thermometer) to measure health status, ranging from worst imaginable health state to best imaginable health state. Descriptive data from the 5 dimensions of Part I can be used to generate a health-related quality of life profile for the subject. Higher scores mean worse outcome. Part II is scored from 0 to 100. The score from Part II can be used to track changes in health, on an individual or group level, over time. Higher scores mean better outcome. | 6 months after V0 visit | |
Secondary | V3 visit- EQ-5D - European Quality of Life Questionnaire | The EQ-5D is a measure of self-reported health outcomes that is applicable to a wide range of health conditions and treatments. It consists of two parts: a descriptive system (Part I) and a visual analogue scale (VAS) (Part II). Part I of the scale consists of 5 single-item dimensions including: mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has a 3 point response scale designed to indicate the level of the problem. Part II uses a vertical graduated VAS (thermometer) to measure health status, ranging from worst imaginable health state to best imaginable health state. Descriptive data from the 5 dimensions of Part I can be used to generate a health-related quality of life profile for the subject. Higher scores mean worse outcome. Part II is scored from 0 to 100. The score from Part II can be used to track changes in health, on an individual or group level, over time. Higher scores mean better outcome. | 9 months after V0 visit | |
Secondary | V4 visit- EQ-5D - European Quality of Life Questionnaire | The EQ-5D is a measure of self-reported health outcomes that is applicable to a wide range of health conditions and treatments. It consists of two parts: a descriptive system (Part I) and a visual analogue scale (VAS) (Part II). Part I of the scale consists of 5 single-item dimensions including: mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has a 3 point response scale designed to indicate the level of the problem. Part II uses a vertical graduated VAS (thermometer) to measure health status, ranging from worst imaginable health state to best imaginable health state. Descriptive data from the 5 dimensions of Part I can be used to generate a health-related quality of life profile for the subject. Higher scores mean worse outcome. Part II is scored from 0 to 100. The score from Part II can be used to track changes in health, on an individual or group level, over time. Higher scores mean better outcome. | 12 months after V0 visit | |
Secondary | V0 visit- FES - Falls Efficacy Scale | FES - Falls Efficacy Scale in points from 0 - 100, Questionnaire, The more, the worse The FES is a questionnaire assessing the confidence level individuals have in performing daily activities without falling. The FES is a 10 item scale where each item is rated on a scale of 1-10. A score of 10 signifies no confidence in these activities; a score of 1 indicates confidence. Higher scores mean worse outcome. Out of a total score of 100, a score of 70 or above indicates the individual has a fear of falling. | 1. day | |
Secondary | V1 visit- FES - Falls Efficacy Scale | FES - Falls Efficacy Scale in points from 0 - 100, Questionnaire, The more, the worse The FES is a questionnaire assessing the confidence level individuals have in performing daily activities without falling. The FES is a 10 item scale where each item is rated on a scale of 1-10. A score of 10 signifies no confidence in these activities; a score of 1 indicates confidence. Higher scores mean worse outcome. Out of a total score of 100, a score of 70 or above indicates the individual has a fear of falling. | 3 months after V0 visit | |
Secondary | V2 visit- FES - Falls Efficacy Scale | FES - Falls Efficacy Scale in points from 0 - 100, Questionnaire, The more, the worse The FES is a questionnaire assessing the confidence level individuals have in performing daily activities without falling. The FES is a 10 item scale where each item is rated on a scale of 1-10. A score of 10 signifies no confidence in these activities; a score of 1 indicates confidence. Higher scores mean worse outcome. Out of a total score of 100, a score of 70 or above indicates the individual has a fear of falling. | 6 months after V0 visit | |
Secondary | V3 visit- FES - Falls Efficacy Scale | FES - Falls Efficacy Scale in points from 0 - 100, Questionnaire, The more, the worse The FES is a questionnaire assessing the confidence level individuals have in performing daily activities without falling. The FES is a 10 item scale where each item is rated on a scale of 1-10. A score of 10 signifies no confidence in these activities; a score of 1 indicates confidence. Higher scores mean worse outcome. Out of a total score of 100, a score of 70 or above indicates the individual has a fear of falling. | 9 months after V0 visit | |
Secondary | V4 visit- FES - Falls Efficacy Scale | FES - Falls Efficacy Scale in points from 0 - 100, Questionnaire, The more, the worse The FES is a questionnaire assessing the confidence level individuals have in performing daily activities without falling. The FES is a 10 item scale where each item is rated on a scale of 1-10. A score of 10 signifies no confidence in these activities; a score of 1 indicates confidence. Higher scores mean worse outcome. Out of a total score of 100, a score of 70 or above indicates the individual has a fear of falling. | 12 months after V0 visit | |
Secondary | V0 visit- ABC - Activities-Specific Balance Confidence Scale | ABC - Activities-Specific Balance Confidence Scale in points from 0 - 150, Questionnaire, The less, the worse Perceived balance confidence was evaluated by Activity Balance Confidence scale (ABC). This test assesses the self-reported patient´s level of confidence while performing a continuum of less and more challenging 16 common daily activities. Higher scores mean better outcome. A score of > 80% indicates high level of functioning | 1. day | |
Secondary | V1 visit- ABC - Activities-Specific Balance Confidence Scale | ABC - Activities-Specific Balance Confidence Scale in points from 0 - 150, Questionnaire, The less, the worse Perceived balance confidence was evaluated by Activity Balance Confidence scale (ABC). This test assesses the self-reported patient´s level of confidence while performing a continuum of less and more challenging 16 common daily activities. Higher scores mean better outcome. A score of > 80% indicates high level of functioning | 3 months after V0 visit | |
Secondary | V2 visit- ABC - Activities-Specific Balance Confidence Scale | ABC - Activities-Specific Balance Confidence Scale in points from 0 - 150, Questionnaire, The less, the worse Perceived balance confidence was evaluated by Activity Balance Confidence scale (ABC). This test assesses the self-reported patient´s level of confidence while performing a continuum of less and more challenging 16 common daily activities. Higher scores mean better outcome. A score of > 80% indicates high level of functioning | 6 months after V0 visit | |
Secondary | V3 visit- ABC - Activities-Specific Balance Confidence Scale | ABC - Activities-Specific Balance Confidence Scale in points from 0 - 150, Questionnaire, The less, the worse Perceived balance confidence was evaluated by Activity Balance Confidence scale (ABC). This test assesses the self-reported patient´s level of confidence while performing a continuum of less and more challenging 16 common daily activities. Higher scores mean better outcome. A score of > 80% indicates high level of functioning | 9 months after V0 visit | |
Secondary | V4 visit- ABC - Activities-Specific Balance Confidence Scale | ABC - Activities-Specific Balance Confidence Scale in points from 0 - 150, Questionnaire, The less, the worse Perceived balance confidence was evaluated by Activity Balance Confidence scale (ABC). This test assesses the self-reported patient´s level of confidence while performing a continuum of less and more challenging 16 common daily activities. Higher scores mean better outcome. A score of > 80% indicates high level of functioning | 12 months after V0 visit | |
Secondary | V0 visit- BDI-II - The Beck Depression Inventory | BDI-II - The Beck Depression Inventory in points from 0 - 63, Questionnaire, The more, the worse The Beck Depression Inventory (BDI-II) is a widely clinically used 21-item self-reported scale to evaluate the severity of depression. The Beck Anxiety Inventory (BAI) is self-reported 21-scale to evaluate the level of anxiety. Both of scales minimum value is 0 and maximum value is 63. Higher scores mean worse outcome | 1. day | |
Secondary | V1 visit- BDI-II - The Beck Depression Inventory | BDI-II - The Beck Depression Inventory in points from 0 - 63, Questionnaire, The more, the worse The Beck Depression Inventory (BDI-II) is a widely clinically used 21-item self-reported scale to evaluate the severity of depression. The Beck Anxiety Inventory (BAI) is self-reported 21-scale to evaluate the level of anxiety. Both of scales minimum value is 0 and maximum value is 63. Higher scores mean worse outcome | 3 months after V0 visit | |
Secondary | V2 visit- BDI-II - The Beck Depression Inventory | BDI-II - The Beck Depression Inventory in points from 0 - 63, Questionnaire, The more, the worse The Beck Depression Inventory (BDI-II) is a widely clinically used 21-item self-reported scale to evaluate the severity of depression. The Beck Anxiety Inventory (BAI) is self-reported 21-scale to evaluate the level of anxiety. Both of scales minimum value is 0 and maximum value is 63. Higher scores mean worse outcome | 6 months after V0 visit | |
Secondary | V3 visit- BDI-II - The Beck Depression Inventory | BDI-II - The Beck Depression Inventory in points from 0 - 63, Questionnaire, The more, the worse The Beck Depression Inventory (BDI-II) is a widely clinically used 21-item self-reported scale to evaluate the severity of depression. The Beck Anxiety Inventory (BAI) is self-reported 21-scale to evaluate the level of anxiety. Both of scales minimum value is 0 and maximum value is 63. Higher scores mean worse outcome | 9 months after V0 visit | |
Secondary | V4 visit- BDI-II - The Beck Depression Inventory | BDI-II - The Beck Depression Inventory in points from 0 - 63, Questionnaire, The more, the worse The Beck Depression Inventory (BDI-II) is a widely clinically used 21-item self-reported scale to evaluate the severity of depression. The Beck Anxiety Inventory (BAI) is self-reported 21-scale to evaluate the level of anxiety. Both of scales minimum value is 0 and maximum value is 63. Higher scores mean worse outcome | 12 months after V0 visit | |
Secondary | V0 visit- BAI - The Beck Anxiety Inventory | BAI - The Beck Anxiety Inventory in points from 0 - 63, Questionnaire, The more, the worse | 1. day | |
Secondary | V1 visit- BAI - The Beck Anxiety Inventory | BAI - The Beck Anxiety Inventory in points from 0 - 63, Questionnaire, The more, the worse | 3 months after V0 visit | |
Secondary | V2 visit- BAI - The Beck Anxiety Inventory | BAI - The Beck Anxiety Inventory in points from 0 - 63, Questionnaire, The more, the worse | 6 months after V0 visit | |
Secondary | V3 visit- BAI - The Beck Anxiety Inventory | BAI - The Beck Anxiety Inventory in points from 0 - 63, Questionnaire, The more, the worse | 9 months after V0 visit | |
Secondary | V4 visit- BAI - The Beck Anxiety Inventory | BAI - The Beck Anxiety Inventory in points from 0 - 63, Questionnaire, The more, the worse | 12 months after V0 visit | |
Secondary | V0 visit- MoCA - Montreal cognitive assessment | MoCA - Montreal cognitive assessment in points from 0 - 30, Scale, The less, the worse.
MoCA is a widely used screening assessment for detecting cognitive impairment. This test consists of 30 points and takes part in 10 minutes from the individual. The Montreal test is performed in seven steps, which may change in some countries dependent on education and culture. The basics of this test include short-term memory, executable performance, attention and focus. Higher scores mean better outcome. |
1. day | |
Secondary | V1 visit- MoCA - Montreal cognitive assessment | MoCA - Montreal cognitive assessment in points from 0 - 30, Scale, The less, the worse.
MoCA is a widely used screening assessment for detecting cognitive impairment. This test consists of 30 points and takes part in 10 minutes from the individual. The Montreal test is performed in seven steps, which may change in some countries dependent on education and culture. The basics of this test include short-term memory, executable performance, attention and focus. Higher scores mean better outcome. |
3 months after V0 visit | |
Secondary | V2 visit- MoCA - Montreal cognitive assessment | MoCA - Montreal cognitive assessment in points from 0 - 30, Scale, The less, the worse.
MoCA is a widely used screening assessment for detecting cognitive impairment. This test consists of 30 points and takes part in 10 minutes from the individual. The Montreal test is performed in seven steps, which may change in some countries dependent on education and culture. The basics of this test include short-term memory, executable performance, attention and focus. Higher scores mean better outcome. |
6 months after V0 visit | |
Secondary | V3 visit- MoCA - Montreal cognitive assessment | MoCA - Montreal cognitive assessment in points from 0 - 30, Scale, The less, the worse.
MoCA is a widely used screening assessment for detecting cognitive impairment. This test consists of 30 points and takes part in 10 minutes from the individual. The Montreal test is performed in seven steps, which may change in some countries dependent on education and culture. The basics of this test include short-term memory, executable performance, attention and focus. Higher scores mean better outcome. |
9 months after V0 visit | |
Secondary | V4 visit- MoCA - Montreal cognitive assessment | MoCA - Montreal cognitive assessment in points from 0 - 30, Scale, The less, the worse.
MoCA is a widely used screening assessment for detecting cognitive impairment. This test consists of 30 points and takes part in 10 minutes from the individual. The Montreal test is performed in seven steps, which may change in some countries dependent on education and culture. The basics of this test include short-term memory, executable performance, attention and focus. Higher scores mean better outcome. |
12 months after V0 visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |